INTRODUCTION
The occurrence of venous thromboembolism in individuals with solid epithelial tumors has been associated with a poor prognosis with more than three-fold higher risk of early death, as compared with cancer patients without thrombosis. 1, 2 This detriment in survival is not only attributable to death from thrombotic complications such as pulmonary embolism. Thrombosis is itself, for many patients, an indicator of an underlying aggressive tumor behavior. There are several molecular links between the prothrombotic state and oncogenic events such as malignant transformation, angiogenesis, in vivo tumor growth and metastasis. These include the upregulation of cyclo-oxigenase-2, plasminogen activator inhibitor 1, and tissue factor (TF) genes and proteins. 3 In solid epithelial tumors, the expression of TF on the cell surface membrane of cancer cells and on circulating microparticles shed from these neoplastic as well as from nonneoplastic cells has a key role in thrombosis and oncogenesis. 4, 5 The mechanisms of thrombosis in individual with hematological malignancies may, however, differ from those with solid tumors. Thrombosis is a frequent feature in individuals with multiple myeloma (MM), particularly those receiving treatment with oral immunomodulatory drugs such as thalidomide or lenalidomide (so-called IMIDs), concomitantly with anthracyclines or dexamethasone, in whom up to a third may develop venous thromboembolism if not given prophylaxis. 6, 7 The lack of impact of thrombosis on survival in MM has recently been reported in large US and European multicenter studies in both, newly diagnosed and relapsed refractory patients. 8, 9 This finding suggests that activation of coagulation and malignant behavior in MM may not be driven by TF on neoplastic plasma cells. Furthermore, a puzzling clinical observation has been that thrombosis in the context of IMID-based therapy may be prevented by the use of prophylactic aspirin. 10 Here, we sought to study the gene expression status of F3 (encoding the TF protein) by microarray analysis in human myeloma cell lines (HMCL) and bone marrow from MM patients, as well as the TF protein expression in myeloma plasma cells in bone marrow biopsies, and to compare the results with solid tumor cell lines.
MATERIALS AND METHODS
Gene expression levels were analyzed in 223 solid tumor cell lines obtained from GlaxoSmithKline (GSK) Cancer Cell Line Genomic Profiling Dataset (https://array.nci.nih.gov/caarray/project/woost-00041) and in 55 HMCLs (Supplementary Table 1 ) using the Affymetrix HG-U133_Plus_2 array. The expression level of F3 (the gene that encodes for TF) was transformed using Plier16 algorithm and the probe intensities were log2 mediannormalized across all cell lines. Additionally, samples from 239 MM patients were also studied for gene expression (data available at www.broadinstitute.org/mmgp/home). All patients provided appropriate informed consent.
Immunohistochemistry (IHC) staining for TF was performed using standard procedures on bone marrow biopsy tissue microarrays (TMA) for 73 patients (in triplicate), using TF positive (nasopharyngeal epithelium, squamous cell carcinoma) and CD138 positive (myeloma) controls. Connective tissue from nasopharyngeal epithelium was used as negative control. We have used these TMA slides in previous publications. 11, 12 Briefly, slides were deparaffinized using xylene-free dewaxing reagent (72 1C, 4 min, EZprep; Ventana Medical Systems, Tucson, AZ, USA) and stained for IHC using a BenchMark ULTRA automated slide stainer (Ventana). Following CC1 alkaline antigen retrieval (95 1C, 8 min.), TMAs were incubated with primary rabbit polyclonal anti-human TF antibody (FL-295, dilution 1:75, 36 1C, 4 min, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Ventana ultraView Universal polymerbased diaminobenzidine detection kit was used for visualization of antibody localization. In order to obtain a double stain with anti-CD138 (positive in plasma cells), the slides were then incubated with primary mouse monoclonal anti-human CD138 (Dako, Carpinteria, CA, USA, Clone MI15, dilution 1:150), followed by polymer-based alkaline phosphatase detection. TMAs were washed thoroughly in between steps using reaction buffer and manually counterstained with Harris haematoxylin, and finally mounted with non-aqueous medium. TF expression by plasma cells was scored semi-quantitatively for staining intensity as negative, 1 þ (weak), 2 þ (moderate) and 3 þ (strongly positive). The percentage of positive cells was recorded.
RESULTS AND DISCUSSION
We found F3 to be commonly expressed in a wide variety of cell lines originated from solid tumors (except for renal cancer cells). Conversely, F3 was absent or minimally expressed in all HMCLs ( Figure 1 ) and in all 239MM patient samples analyzed (data not shown). Protein expression by IHC from 73 triplicate patient TMA cores was negative in 80% of the samples, with the rest showing weak focal cytoplasmic TF in plasma cells. Only three patients had moderate (2 þ ) focal or diffuse cytoplasmic heterogeneous staining, all having at least one negative core. In these cases, none of the plasma cell membranes stained for TF. No samples with strong (3 þ ) plasma cell staining were seen. TF was present in non-plasma cells with diffuse cytoplasmic staining in megakaryocytes and neutrophils and granular staining within macrophages, whereas endothelial cells showed both intracytoplasmic as well as membrane staining (Figure 2) .
Hemostasis, inflammation, angiogenesis and oncogenesis are intricately connected and share many of the same proteins, enzyme products, receptors and cell signaling pathways. Therefore, venous thrombosis has been regarded as a clinical indicator of an underlying biological advantage to cancer growth and metastasis 1,2 TF, a cell-surface membrane glycoprotein that triggers the activation of coagulation by binding to factor VII, is the most likely candidate responsible for the molecular link between thrombosis and malignant tumor behavior, and ultimately for the impact on poor clinical outcome of individuals with solid tumors who develop thrombosis. 4, 5 Genetic events affecting oncogenes (RAS and MET) and tumor suppressor genes (TP53 and PTEN) have been shown to directly enhance TF expression by neoplastic cells.
3 TF-dependent fibrin generation on the surface of circulating neoplastic cells confers an advantage for metastasis. 13 Activated coagulation factors Xa and thrombin as well as TF itself, are able to induce receptor-mediated intracellular signals through protease-activated receptors (PAR1 and PAR 2), which promote invasion and angiogenesis as well as protection from apoptosis.
14,15 Although TF does not affect in vitro proliferation, it is required for adequate tumor vascularization and growth in murine models in vivo. 13 Furthermore, tumor cell TF has been shown to be pro-angiogenic independently of its procoagulant activity by upregulating the generation of vascular endothelial growth factor. 16 These data suggest that tumors expressing TF are associated with an underlying procoagulant state intimately linked to malignant tumor behavior.
In the present study, we found that HMCLs do not express F3 or have a very low level of expression compared with solid tumors. This, however, does not rule out a role for TF from other cellular sources in the development of thrombosis. The potential source of circulating TF is broad and may be different in different disease states. Many cell types, particularly activated endothelial cells and monocytes, can synthesize and express cell surface-bound TF, or shed microparticles bearing TF (MP-TF). 17 Although Negaard et al. 19 argue against a major role of soluble non-microparticle-bound TF in plasma in MM and other hematological malignancies, a recently published study by Auwerda et al. 18 showed MP-TF activity levels are significantly higher in untreated MM patients compared with normal healthy donors. The authors found that MP-TF activity remains elevated in patients who develop venous thromboembolism, but decreases in those that do not. Our findings show that although TF may be relevant to thrombosis in some MM patients, it is most likely not derived from the neoplastic cells. The moderate expression of TF in both bone marrow megakaryocytes and endothelial cells (Figure 2 ) suggests that it is these cells, which are the origin of at least part of the circulating TF-bearing microparticles. As thrombosis does not affect the outcome of most patients with MM, 8, 9 we propose that it is the TF produced by the neoplastic cells themselves that drives malignant behavior, and that TF derived from nonneoplastic cell sources as a result of host response to cancer (acute phase reaction, inflammation and necrosis) or to known prothrombotic treatment regimens, 20 does not affect oncogenesis though it may still be important for the development of thrombosis.
The fact that the vast majority of neoplastic plasma cells do not express TF is not surprising, as, unlike monocytes, lymphocytes do not express TF under physiologic conditions. There is in vitro evidence that phorbolmyristate acetate (PMA)-stimulated activated B lymphocytes can express TF, but this has not been described for plasma cells. 21 MM plasma cells have rarely been shown to contain TF. A single case report shows TF detected by IHC in plasma cells from a patient with MM and DVT. 22 TF found in cells may not necessarily mean that TF is being transcribed by the cell itself. In an elegant study, Egorina et al. 23 have shown that monocytes are the only source of TF in whole blood, and provide solid experimental evidence for a direct transfer of TF from monocytes to granulocytes. Whether neoplastic plasma cells are capable, like neutrophils, of fusion with TF-bearing microparticles derived from other cell types is unknown. Our finding of rare patient samples with moderate TF staining suggests that bone marrow microenvironment may have a role in either promoting expression of TF or possibly supporting direct TF transfer to malignant plasma cells.
Finally, the fact that TF is not expressed by neoplastic plasma cells may explain why heparin, which works in part by inhibiting TF, 24 is not better than aspirin for DVT prophylaxis of patients with MM. 25 In support of our findings, a recent study by Pal et al.
26
shows that promyelocyte-derived cathepsin G may be a more important mediator of thrombosis in the setting of IMID therapy in MM. We speculate that the intravascular nature of MM and other hematopoietic malignancies makes it less likely for them to depend on pro-coagulant factors for disease spread. Something clearly of benefit to solid tumor clones.
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